title: Therapy-related acute myeloid leukemia following treatment with trabectedin for Ewing's sarcoma.
authors.affiliation: Jane Anne Nohl Division of Hematology and Center for the Study of Blood Diseases, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA 90033, USA.
authors.forename: Stephen V
authors.initials: SV
authors.lastname: Liu
authors.forename: Susan
authors.initials: S
authors.lastname: Zneimer
authors.forename: Amir
authors.initials: A
authors.lastname: Tahbaz
authors.forename: Dan
authors.initials: D
authors.lastname: Douer
mesh_terms: D000328:Adult; D018906:Antineoplastic Agents, Alkylating / Q000009:adverse effects* / Q000627:therapeutic use; D001859:Bone Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy; D004149:Dioxoles / Q000009:adverse effects* / Q000627:therapeutic use; D005047:Etoposide / Q000009:adverse effects / Q000627:therapeutic use; D017809:Fatal Outcome; D005260:Female; D017353:Gene Deletion; D015321:Gene Rearrangement; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000235:genetics*; D051788:Myeloid-Lymphoid Leukemia Protein / Q000235:genetics; D016609:Neoplasms, Second Primary / Q000235:genetics*; D012512:Sarcoma, Ewing / Q000188:drug therapy* / Q000532:radiotherapy; D044005:Tetrahydroisoquinolines / Q000009:adverse effects* / Q000627:therapeutic use; D059003:Topoisomerase Inhibitors; D000077606:Trabectedin; D055815:Young Adult
chemical_list: D018906:Antineoplastic Agents, Alkylating; D004149:Dioxoles; D044005:Tetrahydroisoquinolines; D059003:Topoisomerase Inhibitors; D051788:Myeloid-Lymphoid Leukemia Protein; D005047:Etoposide; D000077606:Trabectedin